COVID-19 is still here, but it looks very different from the virus that shut down the world in 2020. The World Health Organization officially declared that COVID-19 no longer constitutes a public health emergency of international concern on May 5, 2023, marking a shift from crisis mode to long-term monitoring. The virus continues to circulate, cause illness, and evolve new variants, but widespread immunity, effective treatments, and updated vaccines have dramatically reduced the toll it takes.
The Emergency Is Over, but the Virus Isn’t Gone
The WHO’s decision to end the emergency designation reflected a sustained decline in COVID-19 deaths, hospitalizations, and intensive care admissions worldwide. That doesn’t mean COVID disappeared. It means the global health system shifted from emergency response to treating COVID-19 as an ongoing, manageable infectious disease, similar to how public health systems handle influenza.
The virus still mutates regularly. As of early 2026, the WHO tracks several variants under monitoring, including KP.3.1.1, NB.1.8.1, and others. None of these have triggered the kind of devastating waves seen with Delta or early Omicron, largely because so much of the population now carries some level of immunity.
Most People Now Have Some Immunity
By late 2022, CDC blood donor data showed that 96.4% of people aged 16 and older had antibodies against SARS-CoV-2 from prior infection, vaccination, or both. Nearly half the population (47.7%) had what researchers call hybrid immunity, meaning protection built from both catching the virus and getting vaccinated. That combination provides stronger, longer-lasting defense than either source alone.
Young adults aged 16 to 29 had the highest rates of hybrid immunity at about 60%, while adults 65 and older had the lowest at roughly 37%. That gap matters because older adults remain the group most vulnerable to severe illness. It’s one reason updated vaccines continue to be recommended, particularly for higher-risk groups.
COVID Now Follows a Seasonal Pattern
One of the biggest shifts is that COVID-19 has settled into a predictable rhythm. Research from temperate climate countries found that COVID-19 waves strongly correlate with flu season. Peaks happen in winter, lows in summer, driven by the same environmental factors that influence flu: temperature, humidity, UV exposure, and time spent indoors. This seasonal pattern makes future waves more predictable and easier to prepare for, though summer surges can still occur on a smaller scale.
Public health agencies now track COVID-19 alongside flu and RSV as part of a broader respiratory virus surveillance system. Wastewater monitoring has become a key tool in this effort. By testing sewage samples, health departments can detect rising viral levels in a community before people show up at hospitals or clinics. This works even for infections that never produce symptoms.
What Happens When You Get COVID Now
For most people with some prior immunity, a COVID infection in 2024 or 2025 looks like a bad cold or mild flu: a few days of fatigue, congestion, sore throat, and possibly fever. Severe outcomes still occur, primarily in older adults, people with weakened immune systems, and those with chronic health conditions.
The CDC simplified its isolation guidance in early 2024, aligning COVID rules with recommendations for other respiratory viruses. If you test positive or feel sick, you should stay home until your symptoms have been improving for at least 24 hours and any fever has been gone for a full day without medication. After that, you can return to normal activities but should take extra precautions for the next five days: wearing a well-fitting mask around others, improving ventilation, washing hands frequently, and keeping distance when possible.
Treatments That Changed the Equation
Antiviral treatment remains available for people at high risk of severe illness. The oral antiviral Paxlovid, taken within the first few days of symptoms, reduces the risk of hospitalization and also lowers how infectious a person is. Modeling by the CDC estimated that treating just 20% of symptomatic patients with Paxlovid over a 300-day period could prevent between 280,000 and 850,000 hospitalizations in the U.S., depending on how fast the virus was spreading. The drug continues to work against Omicron-lineage variants.
Updated Vaccines Work Differently Now
COVID-19 vaccines have shifted to an annual update model, much like the flu shot. In June 2024, the CDC’s Advisory Committee on Immunization Practices recommended updated 2024-2025 COVID-19 vaccines for everyone aged six months and older. For most children five and older and all adults, a single updated dose is recommended regardless of how many previous shots they’ve had. Younger children who haven’t been vaccinated before may need a multi-dose initial series.
In May 2025, the U.S. updated its approach for children and teens, moving COVID-19 vaccination for healthy kids aged 6 months through 17 years to a shared decision-making model. That means it’s offered and discussed with families rather than universally pushed. For older adults and people with compromised immune systems, the recommendation remains straightforward: get the updated dose.
Long COVID Remains a Concern
Perhaps the most significant lingering consequence of the pandemic is long COVID. A nationally representative survey estimated that 7.2% of U.S. adults experienced long COVID in 2022, defined as symptoms persisting three months or longer after infection. The most common symptoms were fatigue (reported by 26.2% of those with long COVID), shortness of breath (18.9%), loss of taste or smell (17.0%), brain fog and memory problems (9.8%), and joint or muscle pain (6.2%). A smaller percentage reported heart palpitations, dizziness, or mood changes.
Not all long COVID is debilitating. About 5% of people with persistent symptoms reported no limitation on their daily activities. But for others, the condition significantly affects work, exercise, and quality of life. Research into causes and treatments continues, and the condition remains one of the less-resolved chapters of the pandemic. Vaccination before infection and prompt antiviral treatment both appear to lower the risk of developing long COVID, though neither eliminates it entirely.
Where Things Stand
COVID-19 has effectively joined the roster of respiratory viruses that circulate every year. It still kills people, particularly the elderly and immunocompromised, but at a fraction of its peak toll. The tools available now, updated vaccines, antiviral treatments, widespread immunity, wastewater surveillance, have transformed it from a global emergency into something closer to a persistent, manageable health threat. The virus keeps evolving, and monitoring continues, but the world it circulates in has fundamentally changed.